Bradley Burnam

Turn Therapeutics(TM), Inc is a pharmaceutical and medical device organization that aims to reduce the human and economic costs of infection and skin disease. Turn Therapeutics(TM is based in Calabasas, CA. The private company's core mission is to innovate and educate in order to render disease obsolete. The company has multiple, mass market-ready, proprietary assets incorporating advanced delivery and healing technologies, including their FDA cleared product, Hexagen® wound dressing, which is non-irritating, non-cytotoxic, and non-sensitizing, as well as suitable for extended-wear. The company was founded by Bradley Burnam, who has been the CEO since incorporation.

Baropace, Inc. is a privately held medical device company located in Ashland, OR. Baropace is focused on the development of pressurepace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction (hfpef). The company has proprietary biotechnologies including a pacemaker control algorithm (pressurepace™) and new sensor technologies working through patient mobile and wearable platforms. Baropace expects to launch a first-in-human clinical trial (relievehtn-i) in the fourth quarter of 2022. Pressurepace™ is limited by federal law to investigational use only and is not approved for sale in any geography. The company was founded in 2019 by Eli Gang and Michael Burnam, who has been the CEO since 2018.